A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Enzastaurin (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms ENGAGE
- Sponsors Denovo Biopharma
- 18 Apr 2024 Status changed from active, no longer recruiting to completed.
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2021 According to a Denovo Biopharma media release, data from this study will be presented at the Society for NeuroOncology (SNO) Annual Meeting (November 18-21, 2021).